FGC
PETX

Financial Gravity Companies’s Aratana Therapeutics, Inc. PETX Stock Holding History

Financial Gravity Companies’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$0 Buy
72
+16
+29% +$71 ﹤0.01% 1745
2017
Q4 		$0 Buy
+56
New +$343 ﹤0.01% 1524

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Financial Gravity Companies's PETX Position: Q1 2018 in Review

Financial Gravity Companies increased its Aratana Therapeutics, Inc. (PETX) stake by 29% in Q1 2018, buying an estimated $71 and bringing the position to 72 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1745.

Financial Gravity Companies first reported a position in PETX in Q4 2017 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold PETX as of Q1 2018.

  • Financial Gravity Companies held 72 shares of Aratana Therapeutics, Inc. worth $0 as of Q1 2018.
  • Financial Gravity Companies bought 16 Aratana Therapeutics, Inc. shares in Q1 2018, an estimated $71.
  • Aratana Therapeutics, Inc. made up ﹤0.01% of Financial Gravity Companies's portfolio in Q1 2018, its #1745 holding.
  • Financial Gravity Companies first reported a position in Aratana Therapeutics, Inc. in Q4 2017 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2018.

Based on Financial Gravity Companies's 13F filing for Q1 2018, filed 4 May 2018.